Solid Biosciences LLC Total Assets
Solid Biosciences LLC total assets. Based on the latest financial reports, Solid Biosciences LLC (SLDB) holds total assets worth $420.58 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Solid Biosciences LLC market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Solid Biosciences LLC (2015–2025)
Total assets of Solid Biosciences LLC from 2015 to 2025. This chart illustrates how Solid Biosciences LLC's total assets have evolved over time, based on quarterly financial data. See Solid Biosciences LLC stock price for real-time trading data and today's change.
Solid Biosciences LLC - Asset Composition Analysis
Solid Biosciences LLC Total Assets Breakdown (December 2025)
Solid Biosciences LLC total assets breakdown as of December 2025. Solid Biosciences LLC's total assets of $420.58 Million consist of 88.4% current assets and 11.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Solid Biosciences LLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Solid Biosciences LLC's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Solid Biosciences LLC's current assets represent 88.4% of total assets in 2025, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 25.8% of total assets in 2025, down from 51.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Solid Biosciences LLC Competitors by Total Assets
Key competitors of Solid Biosciences LLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Solid Biosciences LLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.82 | 9.34 | 10.59 |
| Quick Ratio | 13.82 | 9.34 | 10.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $366.52 Million | $248.79 Million | $216.27 Million |
Solid Biosciences LLC - Advanced Valuation Insights
This section examines the relationship between Solid Biosciences LLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.73 |
| Latest Market Cap to Assets Ratio | 2.90 |
| Asset Growth Rate (YoY) | 23.3% |
| Total Assets | $232.54 Million |
| Market Capitalization | $673.37 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Solid Biosciences LLC's assets at a significant premium (2.90x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Solid Biosciences LLC's assets grew by 23.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Solid Biosciences LLC (2015–2025)
The table below shows the annual total assets of Solid Biosciences LLC from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $232.54 Million | +23.26% |
| 2024-12-31 | $188.66 Million | +14.38% |
| 2023-12-31 | $164.94 Million | -36.62% |
| 2022-12-31 | $260.25 Million | +11.99% |
| 2021-12-31 | $232.38 Million | +35.76% |
| 2020-12-31 | $171.17 Million | +65.43% |
| 2019-12-31 | $103.47 Million | -25.88% |
| 2018-12-31 | $139.60 Million | +83.21% |
| 2017-12-31 | $76.19 Million | +87.50% |
| 2016-12-31 | $40.64 Million | -27.04% |
| 2015-12-31 | $55.70 Million | -- |
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachyca… Read more